Key result
Remdesivir dose-dependently inhibits SARS-CoV-2 viral replication across variants in preclinical models.
Why the study?
Methods were needed to evaluate the therapeutic effect of drugs based on the characteristics of SARS-CoV-2 and its variants during the COVID-19 outbreak.
Does remdesivir inhibit viral replication in Vero-E6 cells infected with SARS-CoV-2?
Does remdesivir inhibit viral replication in Vero-E6 cells infected with SARS-CoV-2?
This study validates an in vitro assay for testing antiviral activity against SARS-CoV-2, demonstrating that remdesivir effectively inhibits viral replication in a dose-dependent manner.
Premature for clinical use; leaves open whether in vitro inhibition predicts in vivo efficacy against SARS-CoV-2.
The outbreak of COVID-19 has become a public health emergency of international concern; thus, it is important to not only develop drugs for treating COVID-19 but also develop a method for evaluating the therapeutic effect based on the characteristics of SARS-CoV-2 and its variants.To test the antiviral activity of a drug against COVID-19, in this study, we established and compared experimental conditions, such as the treatment time and mode of action (dose) of the therapeutic substance, and a test method to evaluate its effectiveness.We optimized an assay for testing antiviral activity by plaque reduction, tissue culture infectious dose 50, and quantitative RT-PCR.These methods were applied to test the antiviral efficacy of the therapeutic against SARS-CoV-2.Antiviral activity testing using in vitro assays against SARS-CoV-2 and its variants was assessed by measuring plaque-reducing or cytopathic effects in Vero-E6 cells.The in vitro assay was validated by evaluating the antiviral activity of remdesivir.Remdesivir reduced SARS-CoV-2 titer without detectable cytotoxicity and successfully inhibited viral replication in a dose-dependent manner.Therefore, we suggest this in vitro assay as an effective method for testing the antiviral activity for a potential repurposed drug against COVID-19 or rapid screening of therapeutic candidates.
No takes yet. Share an insight, caveat, or question.
Nowakowska et al. (2022) studied SARS-CoV-2. Remdesivir vs. Untreated control was evaluated on 50% inhibitory concentration (IC50) against SARS-CoV-2 variants. Remdesivir successfully inhibited viral replication of SARS-CoV-2 and its variants in a dose-dependent manner, with an IC50 ranging from 0.21 to 0.35 µM after 72 hours of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: